Genor Biopharma Holdings Limited (FRA:67N0)
Germany · Delayed Price · Currency is EUR 0.3780
+0.0220 (6.18%)
At close: Nov 26, 2025
Genor Biopharma Holdings Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2018 - 2019 |
| 224 | 206.23 | - | 15.93 | - | 10.33 | Upgrade | |
Revenue Growth (YoY) | 1448.06% | - | - | - | - | -20.77% | Upgrade |
Cost of Revenue | 0.99 | 1.34 | - | 0.98 | - | 2.6 | Upgrade |
Gross Profit | 223.01 | 204.89 | - | 14.95 | - | 7.74 | Upgrade |
Selling, General & Admin | 58.27 | 71.71 | 125.24 | 217.27 | 305.95 | 241.44 | Upgrade |
Research & Development | 143.34 | 169.19 | 484.99 | 583.88 | 612.72 | 696.57 | Upgrade |
Other Operating Expenses | -9.89 | -2.7 | 6.06 | -0.99 | -34.48 | 28.08 | Upgrade |
Operating Expenses | 191.72 | 238.19 | 616.29 | 800.17 | 884.2 | 966.1 | Upgrade |
Operating Income | 31.29 | -33.3 | -616.29 | -785.22 | -884.2 | -958.36 | Upgrade |
Interest Expense | - | -0.11 | -0.89 | -2.86 | -2.36 | -5.54 | Upgrade |
Interest & Investment Income | 45.03 | 32.69 | 29.67 | 28.11 | 23.73 | 3.72 | Upgrade |
Currency Exchange Gain (Loss) | 5.02 | 5.02 | 5.07 | 25.2 | -28.32 | -131.34 | Upgrade |
Other Non Operating Income (Expenses) | -0.17 | -0.17 | -0.15 | -0.16 | -0.25 | -0.12 | Upgrade |
EBT Excluding Unusual Items | 81.17 | 4.12 | -582.59 | -734.92 | -891.39 | -1,092 | Upgrade |
Impairment of Goodwill | - | - | -3.93 | - | - | - | Upgrade |
Gain (Loss) on Sale of Assets | -5.48 | -5.48 | -16.96 | -2.46 | -0.21 | -0.55 | Upgrade |
Asset Writedown | -24.31 | -33.59 | -75.35 | - | - | - | Upgrade |
Other Unusual Items | -0.18 | -0.18 | 1.34 | 4.95 | 25.3 | -1,944 | Upgrade |
Pretax Income | 51.2 | -35.13 | -677.5 | -732.42 | -866.31 | -3,036 | Upgrade |
Income Tax Expense | 23.49 | 17.84 | -2.28 | -2.02 | -0.93 | -5.81 | Upgrade |
Earnings From Continuing Operations | 27.71 | -52.97 | -675.22 | -730.4 | -865.37 | -3,031 | Upgrade |
Minority Interest in Earnings | 1.21 | 1.69 | 0.85 | 0.18 | 0.15 | 3.4 | Upgrade |
Net Income | 28.92 | -51.28 | -674.36 | -730.21 | -865.22 | -3,027 | Upgrade |
Net Income to Common | 28.92 | -51.28 | -674.36 | -730.21 | -865.22 | -3,027 | Upgrade |
Shares Outstanding (Basic) | 519 | 514 | 506 | 504 | 495 | 245 | Upgrade |
Shares Outstanding (Diluted) | 519 | 514 | 506 | 504 | 496 | 245 | Upgrade |
Shares Change (YoY) | 2.19% | 1.44% | 0.39% | 1.63% | 102.62% | -11.43% | Upgrade |
EPS (Basic) | 0.06 | -0.10 | -1.33 | -1.45 | -1.75 | -12.36 | Upgrade |
EPS (Diluted) | 0.06 | -0.10 | -1.33 | -1.45 | -1.77 | -12.36 | Upgrade |
Free Cash Flow | -11.97 | -123.55 | -426.15 | -586.65 | -670.21 | -815.03 | Upgrade |
Free Cash Flow Per Share | -0.02 | -0.24 | -0.84 | -1.16 | -1.35 | -3.33 | Upgrade |
Gross Margin | 99.56% | 99.35% | - | 93.83% | - | 74.87% | Upgrade |
Operating Margin | 13.97% | -16.15% | - | -4928.55% | - | -9276.55% | Upgrade |
Profit Margin | 12.91% | -24.87% | - | -4583.32% | - | -29301.15% | Upgrade |
Free Cash Flow Margin | -5.34% | -59.91% | - | -3682.19% | - | -7889.19% | Upgrade |
EBITDA | 45.89 | -17.25 | -551.01 | -748.56 | -840.19 | -921.92 | Upgrade |
EBITDA Margin | 20.49% | -8.36% | - | - | - | - | Upgrade |
D&A For EBITDA | 14.6 | 16.06 | 65.29 | 36.66 | 44.01 | 36.44 | Upgrade |
EBIT | 31.29 | -33.3 | -616.29 | -785.22 | -884.2 | -958.36 | Upgrade |
EBIT Margin | 13.97% | -16.15% | - | - | - | - | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.